NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Significant Increase in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Rating) was the target of a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 176,100 shares, an increase of 78.8% from the May 15th total of 98,500 shares. Approximately 2.9% of the shares of the company are sold short. Based on an average daily volume of 3,790,000 shares, the short-interest ratio is presently 0.0 days.

NASDAQ:NRSN opened at $1.46 on Monday. The company has a 50 day moving average of $1.82. NeuroSense Therapeutics has a 12-month low of $1.23 and a 12-month high of $8.18.

NeuroSense Therapeutics (NASDAQ:NRSN – Get Rating) last posted its earnings results on Tuesday, May 31st. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06).

Several large investors have recently modified their holdings of the company. Bank of Montreal Can purchased a new stake in shares of NeuroSense Therapeutics in the first quarter valued at $65,000. Jane Street Group LLC purchased a new stake in shares of NeuroSense Therapeutics in the first quarter valued at $173,000. Finally, Citadel Advisors LLC purchased a new stake in shares of NeuroSense Therapeutics in the fourth quarter valued at $135,000. Institutional investors and hedge funds own 43.83% of the company’s stock.

NeuroSense Therapeutics Company Profile (Get Rating)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis.

Featured Stories